EGFR Testing and Erlotinib Use in Non-Small Cell Lung Cancer Patients in Kentucky by Larson, Kara L. et al.
University of Kentucky 
UKnowledge 
Markey Cancer Center Faculty Publications Markey Cancer Center 
8-18-2020 
EGFR Testing and Erlotinib Use in Non-Small Cell Lung Cancer 
Patients in Kentucky 
Kara L. Larson 
University of Kentucky, karallarson@gmail.com 
Bin Huang 
University of Kentucky, bhuan0@uky.edu 
Quan Chen 
University of Kentucky, quan.chen@uky.edu 
Thomas C. Tucker 
University of Kentucky, thomas.tucker@uky.edu 
Marissa Schuh 
University of Kentucky, marissa.schuh@uky.edu 
See next page for additional authors 
Follow this and additional works at: https://uknowledge.uky.edu/markey_facpub 
 Part of the Epidemiology Commons, Oncology Commons, and the Pharmacy and Pharmaceutical 
Sciences Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Repository Citation 
Larson, Kara L.; Huang, Bin; Chen, Quan; Tucker, Thomas C.; Schuh, Marissa; Arnold, Susanne M.; and 
Kolesar, Jill M., "EGFR Testing and Erlotinib Use in Non-Small Cell Lung Cancer Patients in Kentucky" 
(2020). Markey Cancer Center Faculty Publications. 152. 
https://uknowledge.uky.edu/markey_facpub/152 
This Article is brought to you for free and open access by the Markey Cancer Center at UKnowledge. It has been 
accepted for inclusion in Markey Cancer Center Faculty Publications by an authorized administrator of 
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
Authors 
Kara L. Larson, Bin Huang, Quan Chen, Thomas C. Tucker, Marissa Schuh, Susanne M. Arnold, and Jill M. 
Kolesar 
EGFR Testing and Erlotinib Use in Non-Small Cell Lung Cancer Patients in Kentucky 
Notes/Citation Information 
Published in PLOS ONE, v. 15, issue 8, e0237790. 
© 2020 Larson et al. 
This is an open access article distributed under the terms of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author 
and source are credited. 
Digital Object Identifier (DOI) 
https://doi.org/10.1371/journal.pone.0237790 
This article is available at UKnowledge: https://uknowledge.uky.edu/markey_facpub/152 
RESEARCH ARTICLE
EGFR testing and erlotinib use in non-small
cell lung cancer patients in Kentucky
Kara L. LarsonID
1, Bin Huang1,2,3, Quan Chen1, Thomas Tucker1,4, Marissa SchuhID
1,
Susanne M. Arnold1,5, Jill M. Kolesar1,5*
1 Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America, 2 Division
of Cancer Biostatistics, University of Kentucky, Lexington, Kentucky, United States of America, 3 Department
of Internal Medicine, University of Kentucky, Lexington, Kentucky, United States of America, 4 Department of
Epidemiology, University of Kentucky, Lexington, Kentucky, United States of America, 5 Department of
Pharmacy Practice and Science, University of Kentucky, Lexington, Kentucky, United States of America
* jill.kolesar@uky.edu
Abstract
This study determined the frequency and factors associated with EGFR testing rates and
erlotinib treatment as well as associated survival outcomes in patients with non small cell
lung cancer in Kentucky. Data from the Kentucky Cancer Registry (KCR) linked with health
claims from Medicaid, Medicare and private insurance groups were evaluated. EGFR test-
ing and erlotinib prescribing were identified using ICD-9 procedure codes and national drug
codes in claims, respectively. Logistic regression analysis was performed to determine fac-
tors associated with EGFR testing and erlotinib prescribing. Cox-regression analysis was
performed to determine factors associated with survival. EGFR mutation testing rates rose
from 0.1% to 10.6% over the evaluated period while erlotinib use ranged from 3.4% to 5.4%.
Factors associated with no EGFR testing were older age, male gender, enrollment in Medic-
aid or Medicare, smoking, and geographic region. Factors associated with not receiving
erlotinib included older age, male gender, enrollment in Medicare or Medicaid, and living in
moderate to high poverty. Survival analysis demonstrated EGFR testing or erlotinib use was
associated with a higher likelihood of survival. EGFR testing and erlotinib prescribing were
slow to be implemented in our predominantly rural state. While population-level factors likely
contributed, patient factors, including geographic location (areas with high poverty rates and
rural regions) and insurance type, were associated with lack of use, highlighting rural dispar-
ities in the implementation of cancer precision medicine.
Introduction
Lung cancer is the leading cause of cancer death in the United State [1], and Kentucky leads
the nation in both the rate of new cases and deaths due to cancer, with the Appalachian region
carrying the highest cancer burden [2–4]. The high incidence and death rates in Kentucky
demonstrate a clear need for more effective interventions in lung cancer patients.
Clinical studies associating EGFR mutations with better response to tyrosine kinase inhibi-
tors were reported in 2004 [5–7]. Ongoing clinical trials at that time did not require the
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presence of an EGFR mutation as an inclusion criteria, and erlotinib was initially approved in
late 2004 as a monotherapy for the treatment of patients with locally advanced or metastatic
non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
The approval was based on the BR-21 trial, which compared erlotinib to placebo and
demonstrated survival was significantly longer for patients treated with erlotinib. Multivariate
analyses showed improved survival with erlotinib in the EGFR-positive group by immunohis-
tochemistry, however since the multivariate analyses failed to rule out a small erlotinib survival
effect in patients who were EGFR-negative, erlotinib was approved regardless of EGFR
status [8].
The first EGFR mutation test was commercialized in 2005, however EGFR testing recom-
mendations were not included in the American Society of Clinical Oncology (ASCO) and
National Comprehensive Cancer Network (NCCN) guidelines until 2010 [9, 10]. The OPTI-
MAL and EUROTAC trials, which compared erlotinib to standard doublet chemotherapy in
patients with EGFR mutations, demonstrated both improved progression-free survival and
reduced adverse effects in the erlotinib arms. These were published in 2011 and 2012 and sup-
ported a new erlotinib indication in the front-line setting for EGFR mutant locally advanced
or metastatic NSCLC [11, 12]. Erlotinib indications were updated again in 2016 with the publi-
cation of the IUNO trial, which demonstrated no survival benefit in EGFR wild-type individu-
als, and currently erlotinib is only approved in NSCLC for patients with an EGFR mutation
[13]. Current guidelines published by ASCO recommend that all patients with advanced non-
squamous NSCLC, regardless of clinical characteristics such as age, race, or smoking status
should undergo testing for EGFR and other actionable mutations. [14].
Despite the availability of an EGFR mutation test as early as 2005 and recommendations for
routine EGFR mutation analysis as a part of standard care, not all patients are tested. A 2010
NCCN survey found that less than 50% of oncologists tested their patients for EGFR muta-
tions, and that less than 50% of patients who received erlotinib had EGFR testing done. The
same study found that age, location, comorbidity scores, and treatment history of radiation
therapy affected whether or not patients received the testing [15]. A later survey found that
lack of test availability, unfamiliarity with testing benefits, inadequate tissue for testing, patient
refusal, or a lack of access to targeted clinical trials resulted in low mutation testing rates [16].
The purpose of this study is to evaluate EGFR testing and erlotinib use in patients with
NSCLC in Kentucky and identify factors associated with lack of testing or erlotinib treatment
and associated survival.
Materials and methods
Setting
The Kentucky Cancer Registry (KCR) is a population-based central cancer registry for the
Commonwealth of Kentucky. All healthcare facilities that diagnose or treat cancer patients,
including all acute care hospitals and associated outpatient facilities, freestanding treatment
centers, private pathology laboratories, and physician offices, are required to report each case
of cancer to the KCR. The KCR has been part of the Centers for Disease Control and Preven-
tion (CDC) National Program of Cancer Registries since 1994 and the National Cancer Insti-
tute’s (NCI) Surveillance and Epidemiology and End Results (SEER) program since 2000.
KCR has received the highest level of certification from the North American Association of
Central Cancer Registries (NAACCR) indicating its commitment to accuracy, completeness,
and quality [17].
KCR performed a probabilistic data linkage to identify matches between KCR and claims
from Medicaid, state employee insurance and private insurance groups for cancer cases
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diagnosed in 2000–2012. Medicare claims were also acquired from the SEER Medicare data-
base. The final data set consolidated the linked claims data, including cancer cases diagnosed
in 2000–2011, and claims up to 2015 from sources mentioned above [18].
Study population
The cohort was selected from KCR with claims for cases diagnosed in 2007–2011. Patients
must have presented with invasive NSCLC (Stage IIIB–Stage IV), have had continuous health-
care coverage one month prior to the date of diagnosis and one year after, and must have
linked claims data. Over this time period, 5.3% of diagnosed cases occurred in uninsured indi-
viduals who were excluded from the analysis. Genetic test claims were captured within one
month prior to diagnosis and three months after. Drug claims were captured within one year
of diagnosis and could have been any line treatment (Table 1). The final cohort included 4957
individuals.
Demographics variables were extracted from the linked KCR data, including age at diagno-
sis, race, sex, smoking status, education, poverty status, metropolitan status, Appalachian sta-
tus, insurance type, comorbidity, hospital type and distance to a hospital. Education level and
poverty status were determined by percentage of high school completion rate and percentage
of population below poverty range based on the 2000 US Census county estimates, then cate-
gorized into four levels based on the quartiles of their corresponding distributions. Metropoli-
tan status was defined based on the 2013 Rural-Urban County Continuum Codes with values
1–3 as Metro and 4–9 as Non-Metro (https://www.ers.usda.gov/data-products/rural-urban-
continuum-codes.aspx). Appalachian status was determined by the Appalachia Regional Com-
mission (https://www.arc.gov/appalachian_region/CountiesinAppalachia.asp). A variable with
the combination of metro and Appalachian status was also created. The reporting hospitals
were categorized into two types: tertiary academic hospital (University of Kentucky and Uni-
versity of Louisville) or not. Carlson comorbidity index was calculated from the linked claims
data. Using a Great Circle Distance approach, distance between patient residence and their
corresponding hospital was calculated based the geocodes of the locations. Current Procedural
Terminology (CPT) codes and National Drug Codes (NDC) were extracted from claims to
identify the EGFR mutation test and erlotinib prescription.
Statistical analysis
Descriptive analysis of the demographic and clinical factors was performed. χ2 tests were used
to examine associations between demographic/clinical factors and EGFR test/erlotinib pre-
scription. Two logistic regressions were fitted separately to identify significant factors associ-
ated with EGFR test or erlotinib prescription while controlling for other covariates. Kaplan-
Meier plots and Cox regression survival analysis were also performed to examine how EGFR
testing and erlotinib affect overall survival. The final models only kept variables with p-
value < 0.1. All analyses were done using SAS Statistical software version 9.4 (SAS Institute,
Table 1. Codes used to identify EGFR testing and erlotinib.
Code
Type
Codes Used
Erlotinib NDC 69189–0063, 50242–062, 50242–063, 50242–064, 54868–5290, 54868–5447, 54868–5474,
54569–5848, 54569–5847
EGFR CPT 81235,83891, 83894, 83896, 83898, 83903, 83904, 83907, 83909, 83912, 83890, 81401,83969
https://doi.org/10.1371/journal.pone.0237790.t001
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Inc., Cary, North Carolina, USA). All statistical tests were two sided with a P-value� 0.05
used to identify statistical significance.
Ethical considerations
This study was approved by the University of Kentucky IRB #51483. Informed consent was
waived as all data was de-identified before analysis All data was treated highly as confidential
and was only accessible in password-protected files for authorized study staff.
Results
From 2007 to 2011 the percentage of patients presenting with locally advanced or advanced
stage disease that were tested for EGFR mutations increased from 0.1% to 10.6% (Table 2),
while erlotinib use ranged from 3.4% to 5.4% with no trend over time. Demographics, includ-
ing younger age, female gender, non-smokers and not being white or black were associated
with EGFR testing and erlotinib prescribing. Individuals living in areas with high poverty, low
high school attainment, and with Medicare or Medicaid insurance were significantly less likely
to have EGFR testing or an erlotinib prescription. Geographic factors, both distance to an aca-
demic medical center and rural Appalachia, were significantly associated with EGFR testing,
but not erlotinib prescribing.
Factors associated with EGFR testing were assessed through multi-variate logistic regres-
sion analysis (Table 3). Clinical variables, including age, gender and smoking status were asso-
ciated with EGFR testing with younger, female, non-smokers more likely to be tested.
Additionally, with the exception of 2008, the testing likelihood increased significantly for each
year, 2009 (OR = 22.30, CI = 3.00 to 165.41), 2010 (OR = 58.56, CI = 8.12 to 422.26), and 2011
(OR = 113.47, CI = 15.81 to 814.21) compared to 2007 (P =<0.0001) despite overall rates
remaining low. The variables measuring disparities were also significantly associated with a
decreased likelihood of receiving testing. Patients enrolled in Medicaid (OR = 0.19, CI = 0.09
to 0.40) or Medicare (OR = 0.61, CI = 0.44 to 0.84) compared to those with private insurance
(P =<0.0001) were less likely to receive testing. Those patients living in non-metropolitan
areas, whether in Appalachian (OR = 0.51, CI = 0.36 to 0.73) or non-Appalachian regions
(OR = 0.60, CI = 0.40 to 0.89), were also significantly less likely to receive testing (P = 0.0011).
To determine factors associated with erlotinib prescribing, the same variables were exam-
ined through multivariate logistic regression analysis (Table 4). Similarly, younger patients
and female patients were more likely to receive the drug. In addition, those patients enrolled in
Medicaid (OR = 0.55, CI = 0.33 to 0.93) and Medicare (OR = 0.63, CI = 0.46 to 0.87) were sig-
nificantly less likely to receive the drug compared to those enrolled in private insurance
(P = 0.0074). Those patients living in areas with moderate (OR = 1.90, CI = 1.24 to 2.91) and
high poverty (OR = 1.84, CI = 1.22 to 2.79) were also significantly less likely to receive the drug
compared to those living in low poverty (P = 0.0081).
Cox-regression survival analysis was performed to determine factors associated with likeli-
hood of survival in patients with Stage IIIb–IV NSCLC (Table 5). The clinical characteristics
associated with improved survival include younger age, female gender and a low co-morbidity
score. Several other variables predicted survival. When comparing patients living in metropoli-
tan Appalachia (HR = 1.09, CI = 0.93 to 1.28), rural Appalachia (HR = 1.10, CI = 0.97 to 1.25),
and rural non-Appalachian Kentucky (HR = 1.13, CI = 1.04 to 1.23), patients living in rural,
non-Appalachian regions had a significantly decreased likelihood of survival compared to
those living in a metropolitan region (P = 0.0372). Furthermore, patients enrolled in Medicaid
(HR = 1.17, CI = 1.05 to 1.31) and Medicare (HR = 1.11, CI = 1.03 to 1.19) had a significantly
lower likelihood survival of compared to those with private insurance survival (P = 0.0053).
PLOS ONE Uptake of precision medicine in NSCLC in Kentucky
PLOS ONE | https://doi.org/10.1371/journal.pone.0237790 August 18, 2020 4 / 12
Table 2. Bivariate analysis for EGFR testing and erlotinib receipt among NSCLC Stage III and IV patients.
Had EGFR Testing Received Erlotinib
No % Yes % P No % Yes % P
Total 4748 95.8% 209 4.2% 4744 95.7% 213 4.3%
Age 0.0072 0.0058
20–49 162 91.0% 16 9.0% 167 93.8% 11 6.2%
50–64 999 95.4% 48 4.6% 988 94.4% 59 5.6%
65–74 1976 95.9% 85 4.1% 1969 95.5% 92 4.5%
75+ 1611 96.4% 60 3.6% 1620 96.9% 51 3.1%
Gender <0.0001 0.0046
Male 2811 96.7% 96 3.3% 2802 96.4% 105 3.6%
Female 1937 94.5% 113 5.5% 1942 94.7% 108 5.3%
Race 0.0924 <0.0001
White 4438 95.7% 197 4.3% 4441 95.8% 194 4.2%
Black 299 96.8% 10 3.2% 294 95.1% 15 4.9%
Other 11 84.6% 2 15.4% 9 69.2% 4 30.8%
Stage 0.1729 0.2765
Stage IIIb and effusion 278 94.2% 17 5.8% 286 96.9% 9 3.1%
Stage IV 4470 95.9% 192 4.1% 4458 95.6% 204 4.4%
Metro Status 0.0001 0.5738
Metro 2291 94.7% 129 5.3% 2312 95.5% 108 4.5%
Non-Metro 2457 96.8% 80 3.2% 2432 95.9% 105 4.1%
Appalachia Status 0.0053 0.1029
Appalachia 1624 96.9% 52 3.1% 1615 96.4% 61 3.6%
Non-Appalachia 3124 95.2% 157 4.8% 3129 95.4% 152 4.6%
Appalachia and Metro Status 0.0010 0.0629
Appalachia Metro 166 96.5% 6 3.5% 171 99.4% 1 0.6%
Appalachia Non-Metro 1458 96.9% 46 3.1% 1444 96.0% 60 4.0%
Non-Appalachia Metro 2125 94.5% 123 5.5% 2141 95.2% 107 4.8%
Non-Appalachia Non-Metro 999 96.7% 34 3.3% 988 95.6% 45 4.4%
Year of Diagnosis <0.0001 0.2454
2007 858 99.9% 1 0.1% 823 95.8% 36 4.2%
2008 944 99.6% 4 0.4% 910 96.0% 38 4.0%
2009 914 97.5% 23 2.5% 886 94.6% 51 5.4%
2010 1092 94.1% 69 5.9% 1121 96.6% 40 3.4%
2011 940 89.4% 112 10.6% 1004 95.4% 48 4.6%
Insurance Type <0.0001 <0.0001
Private 966 93.0% 73 7.0% 972 93.6% 67 6.4%
Medicaid 502 98.2% 9 1.8% 490 95.9% 21 4.1%
Medicare 3280 96.3% 127 3.7% 3282 96.3% 125 3.7%
High School Attainment <0.0001 0.0176
Very Low 1191 96.4% 44 3.6% 1193 96.6% 42 3.4%
Low 1203 97.3% 33 2.7% 1174 95.0% 62 5.0%
Moderate 1171 96.0% 49 4.0% 1179 96.6% 41 3.4%
High 1183 93.4% 83 6.6% 1198 94.6% 68 5.4%
Poverty 0.0122 0.0032
Low 1179 96.0% 49 4.0% 1193 97.1% 35 2.9%
Moderate 1062 94.1% 66 5.9% 1066 94.5% 62 5.5%
High 1301 96.0% 54 4.0% 1285 94.8% 70 5.2%
(Continued)
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Table 2. (Continued)
Had EGFR Testing Received Erlotinib
No % Yes % P No % Yes % P
Very High 1206 96.8% 40 3.2% 1200 96.3% 46 3.7%
Charlson Comorbidity Index 0.3214 0.1085
0 2074 95.2% 104 4.8% 2071 95.1% 107 4.9%
1 1328 96.0% 56 4.0% 1327 95.9% 57 4.1%
2 682 96.5% 25 3.5% 677 95.8% 30 4.2%
3+ 664 96.5% 24 3.5% 669 97.2% 19 2.8%
Smoking 0.0393 0.0088
No 258 92.8% 20 7.2% 256 92.1% 22 7.9%
Yes 4052 96.0% 170 4.0% 4051 95.9% 171 4.1%
Unknown 433 95.8% 19 4.2% 432 95.6% 20 4.4%
Distance to Academic Hospital 0.0001 0.1477
Less than 20 Miles 1111 93.5% 77 6.5% 1123 94.5% 65 5.5%
20–50 Miles 754 97.2% 22 2.8% 745 96.1% 31 4.0%
50–100 Miles 1707 96.3% 65 3.7% 1701 96.0% 71 4.0%
100+ Miles 1176 96.3% 45 3.7% 1175 96.2% 46 3.8%
https://doi.org/10.1371/journal.pone.0237790.t002
Table 3. Factors associated with having EGFR somatic mutation testing in Stage IIIb–Stage IV NSCLC patients.
Modeling Had EGFR Testing
Variable OR (95% CI) P-Value
Age (ref = 75+) 0.0001
20–49 4.15 (2.17–7.91)
50–64 1.76 (1.16–2.67)
65–74 1.39 (0.98–1.98)
Sex (ref = Male) 0.0142
Female 1.44 (1.08–1.93)
Appalachian Status (ref = Non-Appalachia/Metro) 0.0011
Appalachian/Metro 0.67 (0.28–1.59)
Appalachian/Non-Metro 0.51 (0.36–0.73)
Non-Appalachian/Non-Metro 0.60 (0.40–0.89)
Year of Diagnosis (ref = 2007) <0.0001
2008 3.81 (0.43–34.68)
2009 22.30 (3.00–165.41)
2010 58.56 (8.12–422.26)
2011 113.47 (15.81–814.21)
Insurance (ref = Private) <0.0001
Medicaid 0.19 (0.09–0.40)
Medicare 0.61 (0.44–0.84)
Smoking (ref = No) 0.0266
Yes 0.54 (0.32–0.91)
Unknown 0.83 (0.42–1.66)
OR = odds ratio; CI = confidence interval; (ref) = reference variable
https://doi.org/10.1371/journal.pone.0237790.t003
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Table 4. Factors associated with the receiving erlotinib in Stage IIIb- Stage IV NSCLC patients.
Modeling Receive Erlotinib
Variable OR (95% CI) P-Value
Age (ref = 75+) 0.0077
20–49 2.05 (1.02–4.14)
50–64 1.97 (1.31–2.95)
65–74 1.56 (1.10–2.21)
Sex (ref = Male) 0.0045
Female 1.49 (1.13–1.97)
Insurance (ref = Private) 0.0074
Medicaid 0.55 (0.33–0.93)
Medicare 0.63 (0.46–0.87)
Poverty (ref = Low) 0.0081
Moderate 1.90 (1.24–2.91)
High 1.84 (1.22–2.79)
Very High 1.33 (0.85–2.09)
OR = odds ratio; CI = confidence interval; (ref) = reference variable
https://doi.org/10.1371/journal.pone.0237790.t004
Table 5. Cox-regression survival analysis for Stage IIIb-IV NSCLC patients.
Variable HR (95% CI) P-Value
Age (ref = 75+) <0.0001
20–49 0.65 (0.55–0.77)
50–64 0.76 (0.70–0.83)
65–74 0.79 (0.74–0.85)
Sex (ref = Male) <0.0001
Female 0.88 (0.83–0.93)
Appalachian Status (ref = Non-Appalachia/Metro) 0.0372
Appalachian/Metro 1.09 (0.93–1.28)
Appalachian/Non-Metro 1.10 (0.97–1.25)
Non-Appalachian/Non-Metro 1.13 (1.04–1.23)
Insurance (ref = Private) 0.0053
Medicaid 1.17 (1.05–1.31)
Medicare 1.11 (1.03–1.19)
Poverty (ref = Low Poverty) 0.0516
Moderate 1.10 (1.02–1.20)
High 0.98 (0.90–1.07)
Very High 1.01 (0.88–1.16)
Stage (ref = Stage IV) 0.0320
Stage IIIb and effusion 0.88 (0.78–0.99)
Charlson Comorbidity Index (ref = 3+) <0.0001
0 0.76 (0.70–0.83)
1 0.82 (0.75–0.90)
2 0.85 (0.77–0.95)
EGFR Test (ref = No Test) 0.0003
Received Test 0.77 (0.67–0.89)
Erlotinib Drug (ref = No Drug) <0.0001
Received Drug 0.62 (0.54–0.71)
HR = hazard ratio; CI = confidence interval; (ref) = reference variable
https://doi.org/10.1371/journal.pone.0237790.t005
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Finally, those patients receiving the EGFR test had a significantly increased likelihood of sur-
vival compared to those who had not received the test (HR = 0.77, CI = 0.67 to 0.89,
P = 0.0030). Similarly, those patients that received erlotinib had an increased likelihood of
survival compared to those who did not receive the drug (HR = 0.62, CI = 0.54 to 0.71, P =
<0.0001).
Kaplan-Meier survival estimates indicate that those patients receiving EGFR testing had an
increased survival probability compared to those that did not receive EGFR testing (Fig 1a).
Those that received erlotinib also had an increased survival probability compared to those
patients not receiving the drug, especially during the 0 to 20 month time period (Fig 1b).
Discussion
The original publications outlining the sensitivity of EGFR-positive NSCLC tumors to tyrosine
kinase inhibitors (TKI) were published in 2004, and the first EGFR assay was commercialized
in 2005 [5–7]. Despite this, our analysis found that during the years 2007–2011, EGFR testing
rates remained low. Erlotinib was approved as a second-line therapy in 2004 for metastatic
NSCLC regardless of EGFR status, and its rate of use was also minimal in the years examined
[8].
While EGFR testing rates have increased over time, still not all eligible patients receive test-
ing. A study evaluating NSCLC patients seen in community medical oncology practices in
New Jersey and Maryland showed between 2013 to 2015, 59% of eligible patients were tested
for EGFR mutations, while a second study using data from a national, private health insurance
company found testing rates to be around 61% between the years of 2010 to 2012 [19, 20]. In
comparison, testing rates in Kentucky were substantially lower during this same time period,
with 7% of eligible patients tested in 2010 and 12% tested in 2011, highlighting disparities
between urban, privately insured individuals and rural, Medicare recipients. The time lag
between the first publications in 2004 and the uptake of the EGFR test and erlotinib use could
be due to a number of causes, both at a population level and due to individual patient charac-
teristics. On a population level, the Centers for Medicare and Medicaid Services (CMS) did
not approve reimbursement of the EGFR test until 2008, and ASCO and NCCN did not update
their guidelines until 2010 [9, 10, 21]. Additionally, FDA-approved indications for erlotinib
have changed multiple times since its approval in 2004, with 2013 being the first time it was
indicated specifically for those patients with EGFR mutations. Finally, as each year passed,
patients were more likely to receive the test compared to 2007, the first year of our analysis,
suggesting wider implementation of testing over time.
Our analysis found patient level factors that further influenced testing rates and erlotinib
prescribing. Younger patients and female patients were more likely to be tested for EGFR
mutations and to receive erlotinib. This is possibly due to EGFR mutations occurring more
frequently in younger NSCLC patients as well as in women [22, 23]. Factors that contributed
to patients being less likely to receive the EGFR test were enrollment in Medicare or Medicaid
and living in a rural area regardless of Appalachian status. Patients enrolled in Medicare or
Medicaid and those living in high poverty areas were also significantly less likely to receive the
drug.
While population factors, including delays in reimbursement, development of guidelines,
and evolving FDA indications likely influenced uptake in Kentucky, we anticipate that patient
characteristics associated with decreased testing are over-represented in our population and
contribute to the lower than national average testing rates over the same time period. Specifi-
cally, our population contained a higher number of Medicare/Medicaid patients compared to
the studies described above. In addition, Kentucky’s poverty rate is significantly higher than
PLOS ONE Uptake of precision medicine in NSCLC in Kentucky
PLOS ONE | https://doi.org/10.1371/journal.pone.0237790 August 18, 2020 8 / 12
Fig 1. a. Kaplan-Meier survival curves for NSCLC patients by EGFR testing status b. Kaplan-Meier survival curves for
NSCLC patients by erlotinib status.
https://doi.org/10.1371/journal.pone.0237790.g001
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the national average (KY = 18.3%, national = 14.6%), with several counties in Appalachia
reaching 35–40% [24]. This could result in significant health disparities compared with
national or less rural populations.
Patients that received EGFR testing had increased survival compared to those who did not.
As expected, younger age, female gender, lower stage, and less comorbidities were associated
with improved survival. Other factors associated with better survival included having private
insurance and living in a non-Appalachia, metropolitan area. Since testing itself should not
impact survival, this is likely due to those patients receiving better overall healthcare, related to
better access to care or better insurance coverage. Nationally, patients with cancer living in
rural areas have worse outcomes when compared to those living in urban areas, related to
income and access inequalities, and highlighting these disparities in our population and sug-
gesting better overall healthcare in these patients as a proxy for increasing their chances for
survival.[25, 26] Those patients that received erlotinib also had a significantly better chance of
survival. This could be an effect of the drug or that patients with EGFR mutant positive
NSCLC have an overall better prognosis than those who do not [27].
To our knowledge, this is the largest description of the use of precision medicine in a pre-
dominantly rural population and the first to show the impact of precision medicine implemen-
tation on patient outcomes. It is also the first to look at precision medicine in Appalachia, a
predominantly impoverished and disparate population. Importantly, we demonstrate the
uptake of precision medicine in a rural population and suggest that new testing and treatment
strategies would similarly lag behind urban and academic medical centers. While the manage-
ment of NSCLC has changed over the intervening years, this analysis has several advantages,
including mature survival data and a comprehensive assessment of implementation over an
extended time-period. In addition, data was collected longitudinally using a registry-based
cohort, which allows for a large sample size and minimizes selection bias. Lastly, at the time
that the data was collected, erlotinib was the only EGFR inhibitor available and NGS panel test-
ing was not performed in Kentucky, which provides the opportunity to observe the implemen-
tation of a single precision medicine test and treatment in a population without competing
interventions.
This study is not without its limitations. The EGFR status or the prior treatment history of
the tested individuals is unknown and so we cannot assess the appropriateness of erlotinib pre-
scribing. Only EGFR testing within three months, and erlotinib prescribing within one year of
diagnosis were assessed. It is possible that patients received the testing or the drug outside of
this time window, but the median survival of late stage lung cancer at the time of data collec-
tion was only twelve months, and we anticipate few, if any patients were missed. In addition,
while the number of cases of lung cancer diagnosed in Kentucky were drawn from a popula-
tion-based cancer registry, the analysis of erlotinib prescribing and EGFR testing was con-
ducted with a linked insurance claims database. Therefore, uninsured patients were not
included in the analysis, which represents a selection bias against the poorest end of the spec-
trum. We anticipate that the 5% of uninsured Kentucky patients with lung cancer were even
less likely to receive testing or erlotinib therapy and to have poorer outcomes [28]. Linked
claims were only available for the time period reported, so while these results do not reflect
current practice patterns, the study presented the opportunity to study the implementation of
a single precision medicine intervention without competing interventions. We hypothesize
that precision medicine interventions continue to lag in rural communities and this highlights
the need for further study. Lastly, we could not measure physician-related factors such as avail-
able resources and education.
In conclusion, EGFR testing and prescribing of erlotinib occurred at a low rate in in Ken-
tucky. While population factors likely contributed, patient level factors including residing in
PLOS ONE Uptake of precision medicine in NSCLC in Kentucky
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rural areas and type of insurance were associated with decreased use and reduced survival,
highlighting rural disparities in the implementation of cancer precision medicine.
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